Quetiapine XR 600 mg for mania in bipolarity
About this title
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
Read the official source — NCT00521365Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.
Understand this study
What did researchers investigate?
Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Guadalajara and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 88
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Mexico
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00521365
- Official title
Show the full official title
A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Guadalajara · Mexico City · Monterrey
4 more locations
- San Pedro Garza García
- San Luis Potosí City
- Mérida
- Durango
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Quetiapine 600mg to find out how it affected manic symptoms in people with bipolarity.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine 600mg.
Who was this study for?
Listed age limits: 18 years to 65 years.
